[HTML][HTML] Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in …
SH Lum, B James, G Ottaviano, AM Ewins… - … and Cellular Therapy, 2024 - Elsevier
Data comparing hematopoietic stem cell transplantation (HSCT) using bone marrow (BM) or
peripheral blood stem cell (PBSC) grafts in children after alemtuzumab-based conditioning …
peripheral blood stem cell (PBSC) grafts in children after alemtuzumab-based conditioning …
[HTML][HTML] Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in …
SH Lum, B James, G Ottaviano, AM Ewins… - … and Cellular Therapy …, 2024 - astctjournal.org
Data comparing hematopoietic stem cell transplantation (HSCT) using bone marrow (BM) or
peripheral blood stem cell (PBSC) grafts in children after alemtuzumab-based conditioning …
peripheral blood stem cell (PBSC) grafts in children after alemtuzumab-based conditioning …
Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in …
SH Lum, B James, G Ottaviano… - … and Cellular Therapy, 2023 - discovery.ucl.ac.uk
Data comparing hematopoietic stem cell transplantation (HSCT) using bone marrow (BM) or
peripheral blood stem cell (PBSC) grafts in children after alemtuzumab-based conditioning …
peripheral blood stem cell (PBSC) grafts in children after alemtuzumab-based conditioning …
Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in …
SH Lum, B James, G Ottaviano… - Transplantation …, 2024 - pubmed.ncbi.nlm.nih.gov
Data comparing hematopoietic stem cell transplantation (HSCT) using bone marrow (BM) or
peripheral blood stem cell (PBSC) grafts in children after alemtuzumab-based conditioning …
peripheral blood stem cell (PBSC) grafts in children after alemtuzumab-based conditioning …
Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in …
SH Lum, B James, G Ottaviano, AM Ewins… - … and Cellular Therapy, 2024 - eprints.ncl.ac.uk
Abstract© 2023Data comparing hematopoietic stem cell transplantation (HSCT) using bone
marrow (BM) or peripheral blood stem cell (PBSC) grafts in children after alemtuzumab …
marrow (BM) or peripheral blood stem cell (PBSC) grafts in children after alemtuzumab …